AMP studies demonstrate proof of concept of passive immunization for HIV prevention

The IAS-led Global HIV Vaccine Enterprise welcomes new results from the AMP proof-of-concept studies (HVTN 704/HPTN 085 and HVTN 703/HPTN 081) demonstrating that infusions of the broadly neutralizing monoclonal HIV antibody (bNAb) VRC01 can prevent some HIV infections.

HIV R4P Virtual News

HIV vaccine highlights and spotlights – To help attendees manage their time and navigate a busy programme, the Enterprise has developed an HIV vaccine R&D roadmap which covers active immunization and  passive immunization with broadly neutralizing antibodies (bNAbs), especially VRC01.